Acasti Pharma (ACST) News Today → This is the best new way to score with AI (From Weiss Ratings) (Ad) Free ACST Stock Alerts C$0.58 +0.01 (+1.75%) (As of 03/27/2023) Add Compare Share Share HeadlinesStock Analysis All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative April 6, 2024 | finance.yahoo.comAcasti Pharma Inc. (ACST)March 14, 2024 | edition.cnn.comAcasti Pharma Inc. Class AFebruary 25, 2024 | msn.comAcasti Pharma (ACST) Price Target Increased by 200.00% to 6.12February 12, 2024 | finance.yahoo.comAcasti Announces Third Fiscal Quarter 2024 Financial Results and Business HighlightsDecember 25, 2023 | finance.yahoo.comWill Acasti Pharma (NASDAQ:ACST) Spend Its Cash Wisely?November 14, 2023 | investing.comAcasti Pharma (ACST) Earnings Dates & ReportsNovember 11, 2023 | morningstar.comAcasti Pharma Inc Class A ACSTSeptember 26, 2023 | benzinga.comWhy Acasti Pharma (ACST) Stock Is Exploding HigherSeptember 6, 2023 | technews.tmcnet.comAcasti to Participate in the H.C. Wainwright Global Investment ConferenceAugust 11, 2023 | finanznachrichten.deAcasti Pharma, Inc.: Acasti Announces First Quarter 2024 Financial Results and Business HighlightsJune 23, 2023 | finanznachrichten.deAcasti Pharma Inc.: Acasti Pharma Reports Fiscal Year 2023 Operational ResultsJune 23, 2023 | finance.yahoo.comAcasti Pharma Reports Fiscal Year 2023 Operational ResultsJune 22, 2023 | finance.yahoo.comAcasti Announces Appointment of New Scientific Advisory Board MembersJune 20, 2023 | sg.finance.yahoo.comACST - Acasti Pharma Inc.April 7, 2023 | theglobeandmail.comClosing Bell: Acasti Pharma Inc up on Monday (ACST)April 4, 2023 | seekingalpha.comAcasti Pharma announces CEO transitionMarch 16, 2023 | morningstar.comAcasti Pharma Inc. Centralizes Marketplace for Shares on the Nasdaq with Voluntary Delisting from TSX Venture Exchange | MorningstarMarch 8, 2023 | finance.yahoo.comAcasti Pharma to Participate in Oppenheimer 33rd Annual Healthcare ConferenceMarch 4, 2023 | finance.yahoo.comWe're Hopeful That Acasti Pharma (CVE:ACST) Will Use Its Cash WiselyMarch 1, 2023 | finance.yahoo.comAcasti Pharma Recognizes Rare Disease DayFebruary 28, 2023 | msn.comHas Acasti Pharma (ACST) Outpaced Other Medical Stocks This Year?January 13, 2023 | benzinga.comAcasti Pharma to Present at Sidoti Virtual Investor Conference on January 18November 15, 2022 | seekingalpha.comAcasti Pharma Inc. (ACST) Q2 2023 Earnings Call TranscriptNovember 9, 2022 | it.tmcnet.comAcasti Pharma to Present at Q4 Investor SummitNovember 8, 2022 | tmcnet.comAcasti Pharma to Report Second Quarter 2023 FinancialSeptember 17, 2022 | theglobeandmail.comAcasti Pharma: Top 10 Undervalued Biotechnology Industry Sector Stocks on TSX Venture Exchange (ACST)September 14, 2022 | finance.yahoo.comAcasti Pharma to Participate in the Lytham Partners Fall 2022 Investor ConferenceSeptember 13, 2022 | it.tmcnet.comAcasti Pharma Announces Initiation of Pharmacokinetic Study for GTX-102, the Company's Drug Candidate for the Treatment of Ataxia TelangiectasiaJuly 27, 2022 | finance.yahoo.comAcasti Pharma Announces Initiation of Pharmacokinetic Study for GTX-101, the Company’s Drug Candidate for the Treatment of Postherpetic NeuralgiaJuly 9, 2022 | finanznachrichten.deStock Day Media: Acasti Pharma Inc. Discusses Year-End Results and Clinical Development Progress with The Stock Day PodcastJuly 7, 2022 | finance.yahoo.comAcasti Pharma Inc. Discusses Year-End Results and Clinical Development Progress with The Stock Day PodcastJune 21, 2022 | seekingalpha.comAcasti Pharma, Inc. (ACST) CEO Jan D'Alvise on Q4 2022 Results - Earnings Call TranscriptJune 21, 2022 | seekingalpha.comAcasti Pharma reports GAAP EPS of $0.27 for FY2022May 23, 2022 | stockhouse.comAcasti Pharma Inc. Retains Lytham Partners to Lead Strategic Investor Relations and Shareholder Communication ProgramMay 12, 2022 | apnews.comAcasti Pharma CEO to Present at Microcap Rodeo’s Spring into Action Best Ideas Virtual Conference on May 16thMarch 9, 2022 | finance.yahoo.comAcasti Pharma CEO to Present at the 32nd Annual Oppenheimer Healthcare Conference on March 16thFebruary 7, 2022 | finance.yahoo.comAcasti Pharma Schedules Third Quarter Fiscal 2022 Business Update Conference CallDecember 22, 2021 | benzinga.comThinking about buying stock in Naked Brand, Biondvax Pharmaceuticals, eMagin Corp, Red Cat, or Acasti Pharma?November 24, 2021 | finance.yahoo.comAcasti Pharma CEO to Participate in the Benzinga All Access Event on December 2ndNovember 4, 2021 | finance.yahoo.comAcasti Pharma Schedules Second Quarter Fiscal 2022 Business Update Conference CallOctober 8, 2021 | proactiveinvestors.comAcasti Pharma outlines key benefits of recent Grace Therapeutics acquisitionOctober 6, 2021 | finance.yahoo.comAcasti Pharma Awarded Composition-of-Matter Patents for GTX-101 in Europe, China and Mexico and for GTX-102 in JapanSeptember 29, 2021 | benzinga.comAcasti Pharma Announces Initiation Of Pharmacokinetic Bridging Study For GTX-104August 31, 2021 | msn.comWhy Shares of Acasti Pharma Slumped TuesdayAugust 28, 2021 | benzinga.comAcasti Says 8-For-1 Reverse Stock Split Will Be implemented To Help Regain Nasdaq Compliance Get Acasti Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ACST and its competitors with MarketBeat's FREE daily newsletter. Email Address Does this make you sick? (Ad)The US Dollar Is "Finished" A deteriorating economy, global instability, and a weakened banking system have pushed the U.S. financial system to the brink, imperiling the value of your savings and investments. Get your Free Wealth Protection Kit ACST Media Mentions By Week ACST Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ACST News Sentiment▼0.000.56▲Average Medical News Sentiment ACST News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ACST Articles This Week▼00▲ACST Articles Average Week Get Acasti Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ACST and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Covalon Technologies News Today Aptose Biosciences News Today Ceapro News Today Kane Biotech News Today Sirona Biochem News Today IBEX Technologies News Today Resverlogix News Today Antibe Therapeutics News Today Microbix Biosystems News Today Small Pharma News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (CVE:ACST) was last updated on 5/15/2024 by MarketBeat.com Staff From Our PartnersTrump Asset Seizure Threat Alert: Could Your Savings Be Next?American Hartford Gold GroupDoes this make you sick?Allegiance GoldHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaDemocrats Push to Replace Dollar With Digital Coin, Control Currency.Monetary GoldBiden to Drop BOMBSHELL June 13th?Paradigm PressForget the “Magnificent 7” Tech Companies, Buy This AI Stock InsteadBanyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acasti Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
